ResMed Income from Continuous Operations 2010-2024 | RMD

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

ResMed annual income from continuous operations for 2024 was $1.021B, a 13.75% increase from 2023.
ResMed annual income from continuous operations for 2023 was $0.898B, a 15.15% increase from 2022.
ResMed annual income from continuous operations for 2022 was $0.779B, a 64.26% increase from 2021.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

ResMed annual income from continuous operations for 2024 was $1.021B, a 13.75% increase from 2023.
ResMed annual income from continuous operations for 2023 was $0.898B, a 15.15% increase from 2022.
ResMed annual income from continuous operations for 2022 was $0.779B, a 64.26% increase from 2021.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$203.2B
Stryker (SYK)	$148.2B
Boston Scientific (BSX)	$133.1B
EssilorLuxottica (ESLOY)	$113.5B
Medtronic (MDT)	$109B
Haleon (HLN)	$42.9B
Lonza Group Ag (LZAGY)	$42.1B
GE HealthCare Technologies (GEHC)	$37.7B
Terumo (TRUMY)	$29.2B
Koninklijke Philips (PHG)	$24.4B
Zimmer Biomet Holdings (ZBH)	$22.1B
Insulet (PODD)	$18.4B
Baxter (BAX)	$16.6B
Smith & Nephew SNATS (SNN)	$11.2B
BellRing Brands (BRBR)	$9.5B
Bio-Rad Laboratories (BIO)	$9B
Demant (WILYY)	$8.3B
Lantheus Holdings (LNTH)	$5.5B
TG Therapeutics (TGTX)	$4.7B
Haemonetics (HAE)	$4.3B
ICU Medical (ICUI)	$4.2B
Prestige Consumer Healthcare (PBH)	$4.1B
Perrigo (PRGO)	$3.7B
Envista Holdings (NVST)	$3.5B
Neogen (NEOG)	$3.3B
Agios Pharmaceuticals (AGIO)	$3.1B
Shandong Weigao Medical Polymer (SHWGF)	$3B
GN Store Nord (GNNDY)	$2.8B
QuidelOrtho (QDEL)	$2.6B
Warby Parker (WRBY)	$2.3B